The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
Open accessAbstract
ErbB2 is a receptor tyrosine kinase whose activity in normal cells depends on dimerization with another ligand-binding ErbB receptor. In contrast, amplification of c-erbB2 in tumors results in dramatic overexpression and constitutive activation of the receptor. Breast cancer cells overexpressing ErbB2 depend on its activity for proliferation, because treatment of these cells with ErbB2-specific antagonistic antibodies or kinase inhibitors blocks tumor cells in the G 1 phase of the cell cycle. Intriguingly, loss of ErbB2 signaling is accompanied by a decrease in the phosphotyrosine content of ErbB3. On the basis of these results, it has been proposed that ErbB3 might be a partner for ErbB2 in promoting cellular transformation. To test this hypothesis and directly examine the role of the “kinase dead” ErbB3, we specifically ablated its expression with a designer transcription factor (E3). By infection of ErbB2-overexpressing breast cancer cells with a retrovirus expressing E3, we show that ErbB3 is an essential partner in the transformation process. Loss of functional ErbB2 or ErbB3 has similar effects on cell proliferation and cell cycle regulators. Furthermore, expression of constitutively active protein kinase B rescues the proliferative block induced as a consequence of loss of ErbB2 or ErbB3 signaling. These results demonstrate that ErbB2 overexpression and activity alone are insufficient to promote breast tumor cell division. Furthermore, we identify ErbB3's role, which is to couple active ErbB2 to the phosphatidylinositol 3-kinase/protein kinase B pathway. Thus, the ErbB2/ErbB3 dimer functions as an oncogenic unit to drive breast tumor cell proliferation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Olayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Requirement for neuregulin receptor erbB2 in neural and cardiac development
Lee, K.-F., Simon, H., Chen, H., Bates, B., Hung, M.-C., & Hauser, C. (1995) · Nature · doi:10.1038/378394a0 · Cited by 1,290
PIK3CA is implicated as an oncogene in ovarian cancer
Shayesteh, L., Lu, Y., Kuo, W.-L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., & Gray, J. W. (1999) · Nature Genetics · doi:10.1038/5042 · Cited by 1,155
Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor
Gassmann, M., Casagranda, F., Orioli, D., Simon, H., Lai, C., Klein, R., & Lemke, G. (1995) · Nature · doi:10.1038/378390a0 · Cited by 1,148
Role of Translocation in the Activation and Function of Protein Kinase B
Andjelkovic, M., Alessi, D. R., Meier, R., Fernandez, A., Lamb, N. J. C., Frech, M., Cron, P., Cohen, P., Lucocq, J. M., & Hemmings, B. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31515 · Cited by 1,051
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,036
The biology of erbB-2/nue/HER-2 and its role in cancer
Hynes, N. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90012-4 · Cited by 971
Self-citationTargeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00603.x · Cited by 769
The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses
Naviaux, R. K., Costanzi, E., Haas, M., & Verma, I. M. (1996) · Journal of Virology · doi:10.1128/jvi.70.8.5701-5705.1996 · Cited by 732
Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 705
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.
Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., & Carraway, K. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8132 · Cited by 698
Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
Alimandi, M., Romano, A., Curia, M. C., Muraro, R., Fedi, P., Aaronson, S. A., Fiore, P. P. D., & Kraus, M. H. (1995) · PubMed · Cited by 548
Smart drugs: Tyrosine kinase inhibitors in cancer therapy
Shawver, L. K., Slamon, D., & Ullrich, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00039-9 · Cited by 522
Engineering polydactyl zinc-finger transcription factors
Beerli, R. R., & Barbas, C. F. (2002) · Nature Biotechnology · doi:10.1038/nbt0202-135 · Cited by 495
Self-citationSiegel, P. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2149 · Cited by 442
The Cellular Response to Neuregulins Is Governed by Complex Interactions of the erbB Receptor Family
Riese, D. J., van Raaij, T. M., Plowman, G. D., Andrews, G. C., & Stern, D. F. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.10.5770 · Cited by 368
Prigent, S. A., & Gullick, W. J. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06577.x · Cited by 359
Britsch, S., Li, L., Kirchhoff, S., Theuring, F., Brinkmann, V., Birchmeier, C., & Riethmacher, D. (1998) · Genes & Development · doi:10.1101/gad.12.12.1825 · Cited by 344
Tyrosine kinase inhibitors: From rational design to clinical trials
Traxler, P., Bold, G., Buchdunger, E., Caravatti, G., Furet, P., Manley, P., O'Reilly, T., Wood, J., & Zimmermann, J. (2001) · Medicinal Research Reviews · doi:10.1002/med.1022 · Cited by 324
Positive and negative regulation of endogenous genes by designed transcription factors
Beerli, R. R., Dreier, B., & Barbas, C. F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040552697 · Cited by 305
Self-citationLane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., & Hynes, N. E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3210-3223.2000 · Cited by 298
Self-citationGraus-Porta, D., Beerli, R. R., & Hynes, N. E. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.3.1182 · Cited by 296
Self-citationMutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas.
Rhei, E., Kang, L., Bogomolniy, F., Federici, M. G., Borgen, P. I., & Boyd, J. (1997) · PubMed · Cited by 290
Motoyama, A. B., Hynes, N. E., & Lane, H. A. (2002) · PubMed · Cited by 286
Self-citationBasso, A. D., Solit, D. B., Munster, P. N., & Rosen, N. (2002) · Oncogene · doi:10.1038/sj.onc.1205184 · Cited by 265
A Packaging Cell Line for Lentivirus Vectors
Kafri, T., van Praag, H., Ouyang, L., Gage, F. H., & Verma, I. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.1.576-584.1999 · Cited by 256
Inhibition of protein kinase B/Akt
Hill, M. M., & Hemmings, B. A. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00193-6 · Cited by 245
Fedi, P., Pierce, J. H., di Fiore, P. P., & Kraus, M. H. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.1.492 · Cited by 228
Schrager, C. A., Schneider, D., Gruener, A. C., Tsou, H. C., & Peacocke, M. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90389-6 · Cited by 193
Expression of c-erbB3 protein in primary breast carcinomas
Naidu, R., Yadav, M., Nair, S., & Kutty, M. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.689 · Cited by 190
Münster, P. N., Marchion, D. C., Basso, A. D., & Rosen, N. X. (2002) · PubMed · Cited by 182
Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells
Neve, R. M., Sutterlüty, H., Pullen, N., Lane, H. A., Daly, J. M., Krek, W., & Hynes, N. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203470 · Cited by 180
Self-citationIntracellular expression of single chain antibodies reverts ErbB-2 transformation.
Beerli, R. R., Wels, W. S., & Hynes, N. E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)51027-4 · Cited by 155
Self-citationMills, G. B., Lu, Y., Fang, X., Wang, H., Eder, A., Mao, M., Swaby, R., Cheng, K. W., Stokoe, D., Siminovitch, K., et al. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90290-8 · Cited by 143
Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein
Kim, H., Vijapurkar, U., Hellyer, N. J., Bravo, D., & Koland, J. G. (1998) · Biochemical Journal · doi:10.1042/bj3340189 · Cited by 106
Ram, T. G., Schelling, M. E., & Hosick, H. L. (2000) · PubMed · Cited by 26
Cited by
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Self-citationEpidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
“However, ERBB3 can still be phosphorylated and induce potent downstream signaling [25].”
BackgroundMolecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210477 · Cited by 1,219
Metadata
- Authors
- Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., & Hynes, N. E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-07-09
- Volume
- 100
- Issue
- 15
- Pages
- 8933-8938
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2069526613
- Cited by
- 950
- References
- 43
- FWCI
- 13.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.